{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-024708","form_type":"8-K","ticker":"HURA","cik":"0001498382","company_name":"TuHURA Biosciences, Inc./NV","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.864396+00:00","generated_at":"2026-06-21T20:00:17.131215+00:00","sec_items":["3.03","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Kintara Therapeutics effects 1-for-50 reverse stock split, trading on adjusted basis Nov 14","bullets":["Reverse stock split at 1:50 ratio effective 5:00 p.m. ET on November 11, 2022.","No fractional shares issued; any fractional shares rounded up to nearest whole share.","Common stock continues trading on Nasdaq under ticker KTRA, new CUSIP 49720K200.","Authorized shares of common stock reduced proportionally from 50 to 1.","Board approved the split on October 28, 2022; no stockholder vote required under Nevada law."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-024708","json":"https://secwatch.observer/filing/0000950170-22-024708.json","markdown":"https://secwatch.observer/filing/0000950170-22-024708.md","text":"https://secwatch.observer/filing/0000950170-22-024708.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1498382/000095017022024708/0000950170-22-024708-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1498382/000095017022024708/ktra-20221110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T20:00:17.131215+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5a730498d0ad821706d9d9b087895330d96dbc09","claim":"TuHURA Biosciences, Inc./NV: Effected a one-for-fifty (1:50) reverse stock split of common stock and corresponding reduction in authorized shares via Certificate of Change to Articles of Incorporation (effective 2022-11-11).","evidence_excerpt":"On November 10, 2022, Kintara Therapeutics, Inc. (the “Company”) filed a Certificate of Change to the Company’s Articles of Incorporation, as amended, with the Secretary of State of the State of Nevada (the “Certificate of Change”), which effected, at 5:00 p.m. Eastern Time on November 11, 2022, a one-for-fifty (1:50) reverse stock split (the “Reverse Stock Split”) of both the Company’s issued and outstanding shares of common stock, $0.001 par value per share (the “Common Stock”) and authorized shares of Common Stock.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1498382/000095017022024708/0000950170-22-024708-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2022-11-11"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}